NORRIS MEDICINES LTD. - 524414 - Results-Delay in Financial Results
Standalone Unaudited Financial Results for the quarter ended 30.06.2022 in compliance with Regulation 33 of SEBI (LODR) Regulations, 201527-08-2022
27-08-2022
NORRIS MEDICINES LTD. - 524414 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June, 202227-08-2022
NORRIS MEDICINES LTD. - 524414 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Non-Applicability of Annual Secretarial Compliance Report for the financial year ended 31st March, 202226-08-2022
NORRIS MEDICINES LTD. - 524414 - Board Meeting Intimation for A Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Wednesday, I.E. 31St August, 2022 At 11.00 A.M. At The Registered Office Of The Company At Plot No. 801/P, GIDC Estate, Ankleshwar-393002, Gujara
NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2022 ,inter alia, to consider and approve a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, i.e. 31st August, 2022 at 11.00 a.m. at the Registered Office of the Company at Plot No. 801/P, GIDC Estate, Ankleshwar-393002, Gujara26-08-2022
NORRIS MEDICINES LTD. - 524414 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- IQUBAL ISMAIL PATELDesignation :- Chief Financial Officer04-08-2022
NORRIS MEDICINES LTD. - 524414 - Compliances-Reg.24(A)-Annual Secretarial Compliance
This is to inform you Paid up Equity Share Capital of the Company is less than Rs. 10 crores and Net worth of the Company is less than Rs. 25 crores. Hence, Annual Secretarial compliance Report under Regulation 24A of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 15(2) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 shall not apply to the Company. Please find enclosed the certificate relating to non applicability of Regulation 24A of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 issued from Devesh R. Desai, Practicing Company Secretary.28-05-2022
NORRIS MEDICINES LTD. - 524414 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Pursuant to provisions of regulation 30 and all other applicable regulations, if any, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Mr. Vinay Kishorbhai Rana, has tendered his resignation from the post of Company Secretary and Compliance Officer (KMP) of the Norris Medicines Limited. He has decided to pursue a career outside the Company. The Company has accepted his resignation and he shall cease to be the Company Secretary and Compliance Officer (KMP) with effect from close of working hours of 28th May, 2022.25-05-2022
NORRIS MEDICINES LTD. - 524414 - Intimation Under Regulations 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held on May 25, 2022, have considered, approved and took on record the following;- 1. Audited Financial Results (Standalone) of the Company for the quarter and year ended on March 31, 2022, along with Auditor's Report on Standalone Financial Results. In this regard, please find enclosed: i) Standalone Audited Financial Results of the Company for the quarter and year ended on March 31, 2022; ii) Auditor's Report on Standalone Financial Results; iii) Declaration pursuant to regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 2. Resignation of Mr. Vinay Rana (A42242) from the post of Company Secretary and Compliance officer. The meeting commenced at 11:30 AM and concluded at 2: 30 PM.25-05-2022
NORRIS MEDICINES LTD. - 524414 - Board Meeting Outcome for Intimation Under Regulations 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held on May 25, 2022, have considered, approved and took on record the following;- 1. Audited Financial Results (Standalone) of the Company for the quarter and year ended on March 31, 2022, along with Auditor's Report on Standalone Financial Results. In this regard, please find enclosed: i) Standalone Audited Financial Results of the Company for the quarter and year ended on March 31, 2022; ii) Auditor's Report on Standalone Financial Results; iii) Declaration pursuant to regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 2. Resignation of Mr. Vinay Rana (A42242) from the post of Company Secretary and Compliance officer. The meeting commenced at 11:30 AM and concluded at 2: 30 PM.25-05-2022